CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03598998
Title field or adapter rule: {'original_value': 'A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:29.482433+00:00
Published At: 2024-08-27T00:00:00+00:00
Record Updated At: 2026-10-29
Results Posted At: 2024-08-27
Source Retrieved At: 2026-10-31T22:18:11.341859+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Anaplastic Large Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Hepatosplenic T-Cell Lymphoma", "Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Hepatosplenic T-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Subcutaneous Panniculitis-Like T-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT03598998"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2024-08-27", "type": "ACTUAL"}

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Treatment (pralatrexate and pembrolizumab)'], 'description': 'Given IV', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (pralatrexate and pembrolizumab)'], 'description': 'Given IV', 'name': 'Pralatrexate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.